Uptake Medical
2216Private Company
Total funding raised: $30M
Overview
Uptake Medical is dedicated to transforming the treatment of severe pulmonary diseases through its proprietary vapor ablation platform. Its flagship InterVapor® System is commercially available in key international markets, generating revenue, while U.S. market access remains a pivotal strategic goal pending FDA approval. The company operates as a core subsidiary of Broncus Medical (HKEX: 2216), utilizing this structure for R&D, manufacturing, and commercial expansion across Asia, Europe, and Australia.
Technology Platform
Bronchoscopic Thermal Vapor Ablation (BTVA) platform delivering controlled heated water vapor via bronchoscope for precise tissue ablation in lung diseases.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In emphysema, main competitor is Pulmonx (Zephyr Valve), an implanted device. Uptake's non-implant vapor ablation offers a differentiated mechanism avoiding valve-related complications. In lung cancer ablation, it faces numerous established thermal/mechanical modalities and must prove superior ease and efficacy.